share_log

Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight, Announces $19 Price Target

Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight, Announces $19 Price Target

富国银行将蒙特罗萨治疗公司评级上调至增持,宣布19美元目标价
Benzinga Real-time News ·  2023/01/03 04:37

Wells Fargo analyst Derek Archila upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) from Equal-Weight to Overweight and announces $19 price target.

富国银行分析师德里克·阿奇拉将蒙特罗萨治疗公司(纳斯达克:GLUE)的评级从持平上调至增持,并宣布目标价为19美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发